You are adding an alert for:
Have the CATT Trial Results and Introduction of Aflibercept to the Marketplace Influenced Utilization of Bevacizumab and Ranibizumab for Retinal Diseases?
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: